Not Yet RecruitingNot Applicable

Validation of New Biomarkers for Predicting No-Reflow in STEMI Patients Undergoing Primary PCI

114 participantsStarted 2025-09-01

Plain-language summary

To evaluate the diagnostic value of the selected emerging biomarkers in predicting the no-reflow phenomenon among patients presenting with STEMI undergoing primary PCI. These biomarkers include: HbA1c/C-peptide ratio Albumin-bilirubin (ALBI) score. Neutrophil/HDL ratio

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥ 18 years * Suitable for and undergoing timely primary PCI based on symptoms and clinical judgment * Provision of informed consent Exclusion Criteria: * History of previous MI, PCI, or CABG * Known chronic inflammatory or autoimmune diseases * Advanced renal or hepatic failure * Active infection or malignancy at presentation * Incomplete data or refusal to consent

What they're measuring

HbA1c/C-peptide ratio predictive accuracy for no-reflow phenomenon

Timeframe: Baseline (prior to PCI)

Albumin-bilirubin (ALBI) score predictive accuracy for no-reflow phenomenon

Timeframe: Baseline (prior to PCI)

Neutrophil/HDL ratio predictive accuracy for no-reflow phenomenon

Timeframe: Baseline (prior to PCI)

Trial details

NCT IDNCT07132489

SponsorAssiut University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2028-09-01

Contact for this trial

Hossam E. A. Abdelhafiz

00201143999651 Hossamalaa203040@gmail.com

View on ClinicalTrials.gov More Myocardial Infarction trials